Protein farnesylation is upregulated in Alzheimer's human brains and neuron-specific suppression of farnesyltransferase mitigates pathogenic processes in Alzheimer's model mice

Angela Jeong,¹ Shaowu Cheng,¹ Rui Zhong,¹ David A. Bennett,^{3,4} Martin O. Bergö,⁵ Ling Li^{1,6,7}

¹Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA

³Department of Neurological Sciences, ⁴Rush Alzheimer's Disease Center, Rush University, Chicago, IL 60612, USA

⁵Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden
Graduate Programs in ⁶Neuroscience and ⁷Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA

Authorship note: AJ and SC are co-first authors who contributed equally to this work.

Corresponding author

Ling Li, PhD
Department of Experimental and Clinical Pharmacology
University of Minnesota
2001 6th Street SE
McGuire Translational Research Facility (MTRF) 4-208
Minneapolis, MN 55455
Phone 612-626-2359
Email lil@umn.edu

SC's present address: The key laboratory of Hunan province for integrated traditional Chinese and western medicine on prevention and treatment of cardio-cerebral diseases, Hunan University of Chinese Medicine, Changsha, China.

Abstract

The pathogenic mechanisms underlying the development of Alzheimer's disease (AD) remain elusive and to date there are no effective prevention or treatment for AD. Farnesyltransferase (FT) catalyzes a key posttranslational modification process called farnesylation, in which the isoprenoid farnesyl pyrophosphate is attached to target proteins, facilitating their membrane localization and their interactions with downstream effectors. Farnesylated proteins, including the Ras superfamily of small GTPases, are involved in regulating diverse physiological and pathological processes. Emerging evidence suggests that isoprenoids and farnesylated proteins may play an important role in the pathogenesis of AD. However, the dynamics of FT and protein farnesylation in human brains and the specific role of neuronal FT in the pathogenic progression of AD are not known. Here, using postmortem brain tissue from individuals with no cognitive impairment (NCI), mild cognitive impairment (MCI), or Alzheimer's dementia, we found that the levels of FT and membrane-associated H-Ras, an exclusively farnesylated protein, and its downstream effector ERK were markedly increased in AD and MCI compared with NCI. To elucidate the specific role of neuronal FT in AD pathogenesis, we generated the transgenic AD model APP/PS1 mice with forebrain neuron-specific FT knockout, followed by a battery of behavioral assessments, biochemical assays, and unbiased transcriptomic analysis. Our results showed that the neuronal FT deletion mitigates memory impairment and amyloid neuropathology in APP/PS1 mice through suppressing amyloid generation and reversing the pathogenic hyperactivation of mTORC1 signaling. These findings suggest that aberrant upregulation of protein farnesylation is an early driving force in the pathogenic cascade of AD and that targeting FT or its downstream signaling pathways presents a viable therapeutic strategy against AD.

Keywords

Protein prenylation, farnesyltransferase, cholesterol, isoprenoids, small GTPases, Alzheimer's disease

Introduction

Alzheimer's disease (AD) is the most common cause of age-related dementia, characterized by progressive cognitive decline, and widespread deposition of neuritic plaques and neurofibrillary tangles in the brain. However, the pathogenic mechanisms underlying the development of AD remain elusive. In recent years, genome-wide association studies have identified several other genes besides APOE that are involved in cholesterol metabolism as top genetic risk factors for late-onset AD, generating much attention to the importance of cholesterol-related pathways in AD pathogenesis [1-3]. Cholesterol is one of many products of the mevalonate pathway (**Figure 1**), and farnesyl pyrophosphate (FPP) serves as a branch point for cholesterol and nonsterol isoprenoids synthesis [4]. Emerging evidence suggests that these isoprenoids play important roles in the development of AD [5-8]. Isoprenoids, including FPP and geranylgeranyl pyrophosphate (GGPP), are short-chain lipid molecules. Three enzymes, farnesyltransferase (FT), geranylgeranyl transferase-1 (GGT-1; GGT), and -2 (GGT-2, also known as RabGGT) covalently attach FPP or GGPP to a cysteine residue in the C-terminal CAAX motif of target proteins [9] (**Figure 1**). These posttranslational modification processes, namely farnesylation and geranylgeranylation, are collectively called protein prenylation [10]. Attachment of isoprenoids enhances the lipophilicity at the C-terminus, facilitates the anchoring of the proteins to endomembrane/plasma membranes, and subsequently enables their interactions with downstream effectors. The superfamily of small GTPases, including Ras, Rho, and Rab GTPases, is the most widely studied group of proteins that are modified by prenylation. These small GTPases and their downstream signaling pathways regulate a wide range of cellular processes such as regulation of cell cycle entry, endosomal trafficking, cell adhesion and migration [11-13]. Dysregulation of protein prenylation and dysfunction of small GTPases have been implicated in various disorders, including progeria and neurodegenerative diseases, as well as cancers and cardiovascular or cerebrovascular diseases [7, 8, 14].

Pharmacological inhibition of isoprenoid synthesis using statins [15-18], protein farnesylation using FT inhibitors [19, 20], or inhibition of downstream signaling cascades of Ras and Rho GTPases [19, 21, 22] has shown benefits against amyloid- β (A β)/tau pathologies and synaptic/cognitive dysfunction in cellular and transgenic animal models. In humans, the levels of FPP and GGPP are elevated in the brain of individuals with AD [23, 24], and the overactivation of Ras/Rho GTPases signaling cascade correlates with the progression of amyloid or tangle pathologies [25, 26]. Collectively, these lines of evidence suggest that dysregulation of isoprenoid synthesis and overactivation of Ras/Rho GTPases pathways influence the pathogenesis of AD. However, the dynamics of protein prenylation *per se* in human brains is unknown and the specific roles of neuronal prenyltransferases are not understood. Further, pharmacological manipulations may be compromised by off-target effects, and genetic approaches that directly target the prenyltransferases are required to unravel the role of protein prenylation in the pathogenic process of AD.

Previously, we have shown that systemic haplodeficiency of either FT or GGT reduces A β deposition and neuroinflammation; however, intriguingly, only FT haplodeficiency rescues cognitive deficits in the APP/PS1 transgenic mouse model of AD [27], suggesting distinct roles of FT and GGT in regulating neuronal function. In follow-up studies, we found that GGT haplodeficiency significantly impairs synaptic and cognitive function whereas FT haplodeficiency has no adverse effects under physiological conditions [28, 29], indicating

FT as a safer therapeutic target than GGT. Here, using postmortem brain tissue samples from individuals at different stages of AD, namely no cognitive impairment (NCI), mild cognitive impairment (MCI), or Alzheimer's dementia, we show that FT, but not GGT, is upregulated in AD brains. Correspondingly, an exclusively farnesylated protein, H-Ras, is elevated in its membrane-associated form, and its downstream effector ERK is over-activated in the brain of individuals with MCI as well as AD. To elucidate the direct impact of neuronal FT on the pathogenic process of AD, we generated forebrain neuron-specific FT knockout in APP/PS1 mice, followed by a battery of behavioral assessments, biochemical assays, and unbiased transcriptomic analysis. Our results demonstrate that the forebrain neuron-specific FT deletion improves memory function and reduces brain A β load in APP/PS1 mice through suppressing APP processing and reversing the pathogenic hyperactivation of mTORC1 signaling. These findings suggest that aberrant upregulation of FT and subsequent protein farnesylation is an early driving force in the pathogenic cascade of AD and that overactivation of downstream signaling pathways contributes to the development of cognitive impairment and neuropathology. Therefore, targeting FT and/or its downstream effectors presents a promising approach to mitigate neuropathology and preserve memory function in AD.

Materials and Methods

Human brain tissue samples

Frozen human dorsolateral prefrontal cortex (Brodmann area 9/46) samples from participants of Religious Orders Study (ROS) were obtained from Rush Alzheimer's Disease Center, Chicago, IL. Details on the overall study design as well as the antemortem and postmortem neuropathological assessment procedures of ROS were reported previously [30]. The study was approved by an Institutional Review Board of Rush University Medical Center, and all participants signed informed consent, an Anatomic Gift Act, and a repository consent to allow their tissue and data to be shared. Brain samples from 60 participants were obtained, with 20 samples from each of three different cognitive diagnosis groups—no cognitive impairment, mild cognitive impairment, and Alzheimer's dementia, independent of neuropathological indices, as previously described [31, 32]. Mean age at death, education level, post-mortem interval (PMI), and sex were matched among the three groups as closely as possible upon sample selection (**Table 1**).

Animals

APP/PS1 double transgenic mice (B6C3-Tg (APP^{swe}, PSEN1 Δ E9) 85Dbo/J; stock# 004462) were purchased from The Jackson Laboratory (Bar Harbor, ME). To generate forebrain neuron-specific FT knockout, mice homozygous for floxed alleles for the FT β -subunit (FT^{fl/fl}) [33] were bred with the CamKII α -Cre recombinase mice [34] to produce FT^{fl/+} Cre+ mice, followed by further crossing with FT^{fl/fl} to generate homozygous forebrain neuron-specific FT-knockout mice (FT^{fl/fl}Cre+). Meanwhile, APP/PS1 mice were bred with FT^{fl/fl} mice in a similar manner to generate APP/PS1 mice harboring homozygous floxed FT (APP/PS1/FT^{fl/fl}). Breeding APP/PS1/FT^{fl/fl} mice with FT^{fl/fl}Cre+ generated littermates with four different genotypes: APP/PS1/FT^{fl/fl}Cre+ (APP/PS1/FTnKO), APP/PS1/FT^{fl/fl}Cre- (APP/PS1), FT^{fl/fl}Cre+ (FTnKO), and FT^{fl/fl}Cre- (WT). Weanlings were PCR genotyped with DNA extracted

from tail/ear biopsies. Both males and females were included. Behavioral assessments were performed at 9 months of age and brain samples were collected at 10 months of age for biochemical analyses. All animal procedures used for this study were prospectively reviewed and approved by the Institutional Animal Care and Use Committee of the University of Minnesota (IACUC protocol # 1908-37310A).

Assessment of mouse behavioral function

Three behavioral tests were performed in a consecutive order to assess AD-related behaviors: the open field test (days 1-3) for exploratory behavior in response to environmental stimuli, the elevated plus-maze test (days 4 and 5) for anxiety, and the Morris water maze test (days 6–11) for spatial learning and memory. All procedures have been previously described using the ANYMAZE system and instruments (San Diego Instruments, San Diego, CA) [27, 35, 36]. Briefly, during the open field test, mice were placed in an open square box and allowed to explore for 5 minutes. The path length and the time spent in the central zone were recorded. For the elevated plus-maze, mice were allowed to explore the two open and closed arms for 5 minutes while the path length and the time spent in the open arms were recorded. The Morris water maze test was performed using a round basin filled with water surrounded by external visual cues for orientation. The testing paradigm included the acquisition learning phase with 4 trials daily for 5 consecutive days (hidden platform), followed by the probe trial for memory retention the day after (no platform), and then the visible platform trial to assess visual acuity. The escape latency and swim path length were recorded during all trials.

Preparation of brain tissue homogenates, and membrane and cytosolic fractions

Post-mortem human brain tissue samples (~ 50 mg) were homogenized in 300 µl low osmotic lysis buffer (5mM Tris-HCl pH 7.4, 2 mM EDTA) supplemented with protease inhibitors and phosphatase inhibitors. An aliquot was homogenized further in the equal volume of 2x Laemmli SDS buffer, sonicated, and centrifuged at 13,000 x g for 15 minutes. The supernatant was saved as the total brain tissue homogenate for immunoblot analysis. Another aliquot of the homogenate was centrifuged at 1,500 x g for 15 minutes at 4°C and the supernatant was then centrifuged at 100,000 x g for 1 h at 4°C in a Beckman Coulter Optima™ MAX-UP Ultracentrifuge using the TLA-120.1 fixed-angle rotor. The resulting supernatant was collected as the cytosolic fraction. The pellet was washed and re-suspended in the equal initial volume of lysis buffer as the membrane fraction. Both cytosol and membrane fractions were added with 5x Laemmli SDS sample buffer and equal volumes of the fractions were subjected to immunoblot analysis.

Mouse brain tissue samples were collected and processed as described previously [27, 37, 38]. Briefly, mice were deeply anesthetized and transcardially perfused with ice-cold PBS. Brains were harvested and cut sagittally into left and right hemispheres. The left hemisphere was fixed in 4% paraformaldehyde for immunohistochemical analysis. The cortex, hippocampus, and cerebellum were dissected from the right hemisphere, snap-frozen in liquid nitrogen, and stored at -80°C until processed for immunoblot analysis and ELISA.

Cell culture and treatment

Human neuroblastoma SH-SY5Y cells stably transfected with the wild-type APP695 construct or empty (mock) pCEP4 mammalian expression vector (a kind gift from Dr. Gunter Eckert, University of Giessen, Germany) were cultured as previously described [39]. To study the effect of a farnesyltransferase inhibitor, cells were incubated in the growth media added with 1 μ M tipifarnib (Selleck cat# S1453) or vehicle (dimethyl sulfoxide, DMSO) for 48 hours. Cells were harvested in PBS containing 1% triton x-100 supplemented with protease inhibitor and phosphatase inhibitor cocktails, lysed by sonication, and subjected to immunoblot analysis.

Immunoblot analysis

The procedures for immunoblot analyses have been described previously [27, 37, 38]. Briefly, total brain tissue and cellular lysates or the cytosolic and membrane fractions were subjected to 12% or 15% SDS-PAGE under the reducing condition, and proteins were transferred to PVDF membranes. Primary and secondary antibodies used are listed in **Table 3**. The membranes were treated with the Western Lightning Plus ECL detection reagent (PerkinElmer Life Sciences, catalog no. NEL103001EA) or Clarity Western ECL substrate (Bio-Rad). Signals were captured by exposing to HyBlot CL films (Denville, catalog no. E3018) or using the iBright™ imaging system (Invitrogen). ImageJ software was used for densitometry analysis.

Amyloid- β ELISA

Frozen mouse cortical and hippocampal samples were processed as described previously [27, 37, 38]. Briefly, brain samples were homogenized sequentially in carbonate and guanidine buffers to obtain the carbonate-soluble and carbonate-insoluble (guanidine-soluble) fractions. The levels of A β in these fractions were determined with A β 40- and A β 42-specific ELISA kits (KHB3481 and KHB3441, ThermoFisher) following the manufacturer's protocol.

Immunohistochemical analysis

Protocols for immunohistochemical analysis have been described previously [27, 37, 38]. Briefly, mouse brain hemispheres prefixed with 4% PFA for 48 hours were sectioned at 50 μ m using a Vibratome (Leica Microsystems Inc). Immunostaining of free-floating sections was performed using the ABC kit (Vector Laboratories, Burlingame, CA). The primary antibody 6E10 was used for assessing A β deposition, and IBA-1 antibody was used for assessing activated microglia. Detailed information on antibodies is available in **Table 3**. Immunoreactivity of A β and IBA-1 in cortical and hippocampal areas was quantified using Image-Pro Plus (MediaCybernetics, Rockville, MD) and Fiji/Image J.

RNA extraction, library preparation, and sequencing

Eighteen mice (9-10 months) were used for transcriptome analysis of the brain: 6 APP/PS1/FTnKO, 6 APP/PS1, and 6 WT controls. The Aurum™ Total RNA Fatty and Fibrous Tissue Kit (732-6830; Bio-Rad) was used to extract total RNA from the frontal cortex following the manufacturer's instructions. RNA quantity was measured using Quant-iT RiboGreen Assay Kit (ThermoFisher), and the quality was determined by the Agilent

Bioanalyzer system. An RNA integrity number (RIN) value of 8.0 or greater (marginal 7.6-7.9) was used for the RNA library preparation. RNA-seq libraries were prepared using Illumina TruSeq Stranded mRNA Kit and sequenced using Illumina NovaSeq 6000 platform, generating 20 million reads per sample on a 150-bp paired-end run. All quality control, library preparation and sequencing were conducted at the University of Minnesota Genomics Center.

RNA sequencing read mapping and data analysis

The raw reads were trimmed using Trimmomatic v0.33, and the trimmed reads were aligned to the GRCm38 reference genome using Hisat2 v2.1.0. The gene-level read counts were generated from the mapped reads using featureCounts. Downstream differential expression analysis was carried out using DESeq2 v3.12 [40] in R v.3.6.2. Multi-dimensional scaling (MDS) plot-diagnostics identified a non-transgenic WT sample as an outlier. Therefore, the sample was excluded from the differential gene expression analysis. A model was built to test the effect of genotype, adjusting for sex (design=~sex + genotype). Wald test was performed for each gene and the attained p-values were corrected for multiple testing to using the Benjamini-Hochberg method. A differentially expressed gene was defined as FDR < 0.05. Gene set enrichment analysis and the transcription factor-gene co-occurrence analysis were conducted using Enrichr [41, 42] and Ingenuity Pathway Analysis. Volcano plots and Z-score heatmaps were generated in GraphPad Prism 8.

Statistical Analysis

Data are expressed as means $\pm$ standard error (SE). Statistical tests were carried out using R and GraphPad Prism 8. The normality of the data was tested with Shapiro-Wilk test. For comparing multiple groups, Welch's ANOVA followed by post-hoc Dunnett's multiple comparison tests were used for normally distributed data, whereas Kruskal-Wallis followed by Wilcoxon rank-sum test was used for non-normally distributed data. For comparing immunoblot results of membrane-associated or phosphorylated proteins between paired samples, the Wilcoxon signed-rank test was used. For comparisons of behavioral performance over consecutive days, repeated measures two-way ANOVA was conducted followed by post-hoc Sidak's multiple comparisons. To compare differences between two groups, the Student's t-test was used. The p -value < 0.05 was considered statistically significant.

Results

Elevated FT expression in AD brains accompanied by an increase in H-Ras farnesylation and activation of downstream signaling

Previous studies have reported upregulation of isoprenoids biosynthesis in AD brains as evidenced by an increase in the level of isoprenoids and in the mRNA expression of farnesyl pyrophosphate synthase (FPPS) and geranylgeranyl pyrophosphate synthase (GGPPS) [23, 24]. However, little is known whether the elevation in isoprenoids leads to increased prenylation of target proteins including small GTPases and activation of their downstream signaling pathways. To evaluate the levels of protein prenylation during the progression of

AD, postmortem human brain tissue samples were obtained from the Religious Orders Study (ROS) participants with three different clinical diagnoses –NCI, MCI, and Alzheimer’s dementia [30]. Sixty individuals (20 from each group), matched for age, sex, and education, were selected for this study solely based on clinical diagnosis independent of neuropathological scores. Demographic and pathology information of the selected participants are summarized in **Table 1**.

First, to measure the protein expression of FT and GGT, the brain tissue homogenates were subjected to immunoblot analyses (**Figure 2A**). The results showed that FT levels were significantly elevated in AD brains and a trend of increase in the MCI group (**Figure 2B**), whereas GGT levels were similar among the three groups (**Figure 2C**). Then, we proceeded to determine whether elevated FT leads to an increase in protein farnesylation. Given that prenylation facilitates membrane association of target proteins, we isolated prenylated proteins from unprenylated proteins by separating the membrane and cytosolic fractions of the brain lysates using analytical ultracentrifugation as previously reported [33, 43]. H-Ras, unlike other Ras isoforms such as N-Ras or K-Ras that can be alternatively geranylgeranylated upon inhibition of FT, is exclusively farnesylated [44]. Thus, H-Ras was selected to assess protein farnesylation in the brain samples. Immunoblot analyses showed that membrane-associated (farnesylated) to cytosolic (unfarnesylated) H-Ras ratios were more than 3-fold higher in MCI and 4-fold higher in AD brains compared with NCI (**Figure 2, F and G**). Notably, there was no difference in total H-Ras levels in the unfractionated brain tissue homogenates among the three groups (**Figure 2, C and D**), indicating the specific increase in the farnesylated H-Ras in MCI and AD brains.

It is well known that the extracellular signal-regulated kinase (ERK) is a key downstream effector of Ras and its activity is regulated by phosphorylation status [45]. To determine if the elevated farnesylated H-Ras led to changes in the activation of downstream signaling, we measured phosphorylated (activated) and total ERK levels (**Figure 2H**). Consistent with the farnesylated H-Ras levels, phosphorylated-to-total ERK ratios were approximately 2-3 fold higher in MCI and AD brains compared with those with NCI (**Figure 2I**). Further, the levels of membrane/farnesylated H-Ras were positively correlated with the levels of FT (**Figure 2J**) and phosphorylated-to-total ERK ratios (**Figure 2K**), respectively. Taken together, these results suggest that upregulation of FT expression, along with subsequent increase in protein farnesylation and overactivation of downstream signaling pathways, is an early event in the pathogenic cascade of AD.

Generation of forebrain neuron-specific FT knockout in APP/PS1 mice

Next, we tested whether direct genetic suppression of FT could modify the pathogenic process of AD. Previously, we have shown that germline/systemic FT heterozygous deletion rescues cognitive function and mitigates amyloid pathology as well as neuroinflammation in the APP/PS1 transgenic mouse model of AD [27]. To dissect the specific role of neuronal FT in AD pathogenesis and to circumvent the impact of FT deletion during the embryonic development, we crossed FT-floxed (FT^{f/f}) mice with the CaMKII α promoter-driven Cre recombinase (Cre⁺) transgenic mice to generate conditional FT knockout mice (FTnKO) (**Figure 3A**), in which FT is selectively deleted in the forebrain neurons postnatally [33, 34]. To confirm the age dependence and brain regional specificity of FT deletion, cortical, hippocampal, and cerebellar tissue lysates of the conditional FT knockout mice were

subjected to immunoblot analyses for the β subunit of FT and HDJ-2, a well-known farnesylated protein that is widely used as a marker for farnesylation [46]. As expected, the results showed greater reduction of FT with increasing age, accompanied by an increase in unfarnesylated HDJ-2 in the cortex and hippocampus, but not in the cerebellum (**Figure 3B**). Further, immunoblot analysis of membrane and cytosolic fractions of cortical tissue lysates from FTnKO mice showed reduced membrane localization of FT substrates, H-Ras and Rheb (Ras homolog enriched in brain), while the membrane association of a GGT substrate RhoA were not affected by conditional FT knockout (**Figure 3C**). These results demonstrated the specificity of forebrain FT knockout in these mice. To investigate the role of neuronal FT in the pathogenic process of AD, FT^{fl} Cre⁺ mice were crossed with APP/PS1/FT^{fl} to produce APP/PS1 mice with neuronal FT knockout (APP/PS1/FT^{fl}/Cre⁺, designated as APP/PS1/FTnKO), and littermate APP/PS1 controls (APP/PS1/FT^{fl}/Cre⁻, designated as APP/PS1), along with FT^{fl}/Cre⁺ (FTnKO) and FT^{fl}/Cre⁻ (wild-type, WT) mice.

Improved spatial learning and memory in neuronal FT knockout APP/PS1 mice

To evaluate whether forebrain neuronal FT deletion affects neurobehavioral function, APP/PS1/FTnKO and APP/PS1 mice were subjected to a battery of behavioral tests including the open field test, elevated plus maze test, and the Morris water maze test at 9 months of age. There were no significant differences in locomotor response and exploratory behavior between the two groups assessed by the open field test (**Table 2**). Interestingly, in the elevated plus maze test, APP/PS1/FTnKO mice spent significantly longer time in the open arm than APP/PS1 mice on the second day of the test, suggesting that forebrain neuronal FT deletion reduced anxiety in APP/PS1 mice (**Table 2**). Hippocampus-dependent spatial memory acquisition and retention were evaluated using the Morris water maze test (**Figure 4A**). Even though the mean escape latencies during the 5-day acquisition phase were not significantly different between the two groups, the repeated measures two-way ANOVA revealed a significant interaction between genotype and day during the test, indicating a steeper/faster learning curve in APP/PS1/FTnKO mice (**Figure 4B**). Consistently, the probe trial, conducted 24 hours later to evaluate the memory retention, showed that APP/PS1/FTnKO group spent significantly more time in the target quadrant compared with APP/PS1 group (**Figure 4C**), indicating improved memory performance in APP/PS1/FTnKO mice. To determine whether forebrain neuron-specific FT deletion had any effects on non-cognitive parameters, the visible platform version of the Morris water maze test was conducted. The results showed that there were no significant differences in the escape latencies to reach the visible platform between the two groups (7.7 ± 1.5 sec vs. 6.9 ± 0.8 sec), indicating neuronal FT deletion did not affect the visual acuity or swimming ability. Taken together, these results demonstrated that forebrain neuron-specific deletion of FT reduced anxiety and improved spatial learning and memory function in APP/PS1 mice.

Reduced cerebral amyloid load and neuroinflammation in neuronal FT knockout APP/PS1 mice

To investigate whether the behavioral improvement in APP/PS1/FTnKO mice was accompanied by any changes in neuropathology, we assessed cerebral amyloid load and associated neuroinflammation. First, we measured A β 40 and A β 42 levels in the carbonate-soluble and carbonate-insoluble (guanidine-soluble) fractions in the cortical and hippocampal lysates using A β species-specific ELISA. A β 40 and A β 42 levels in the carbonate-soluble

fraction were markedly reduced by approximately 40-50% in APP/PS1/FTnKO mice compared with APP/PS1 controls in both cortical and hippocampal regions (**Figure 5, A and C**). Similarly, both guanidine-soluble A β 40 and A β 42 were significantly reduced in the hippocampus. Interestingly, in the cortex, guanidine-soluble A β 40 was evidently reduced whereas there was only a trend of reduction for A β 42 (**Figure 5, B and D**). Importantly, the total levels of A β in both soluble and insoluble fractions of the cortex or hippocampus were substantially reduced in APP/PS1/FTnKO mice compared with APP/PS1 controls (**Figure 5**).

Consistent with the ELISA data, immunostaining of A β on brain sections using 6E10 antibody revealed a significant reduction of amyloid plaque deposition in the cortex and hippocampus in APP/PS1/FTnKO mice (**Figure 6, A-C**). Careful inspection of amyloid plaques suggested that forebrain neuron-specific deletion of FT appeared to modify the size of the plaques. Thus, a sub-analysis was performed to quantify the size distribution of 6E10-positive amyloid plaques. Intriguingly, the results showed that in both the cortex and hippocampus, small (<20 μ m) and medium (20-50 μ m) plaques were significantly reduced, whereas large (>50 μ m) plaques were not significantly reduced in APP/PS1/FTnKO mice compared with APP/PS1 mice (**Figure 6, D and E**). These results suggest that neuronal FT deletion leads to a substantial reduction in the formation of nascent amyloid plaques, which results in an overall reduction of A β deposition in the brain. As β -amyloidosis is often associated with neuroinflammation, the activation status of microglia was assessed next by immunostaining of IBA-1. The results showed a significant reduction in microglial activation in the cortex of APP/PS1/FTnKO compared with APP/PS1, while not in the hippocampus (**Figure 6, G and H**). Together, these findings demonstrate that forebrain neuron-specific deletion of FT reduces amyloid pathology and associated neuroinflammation, contributing to the improvement of cognitive function in APP/PS1/FTnKO mice.

Reduced proteolytic processing of APP in neuronal FT knockout APP/PS1 mice

To elucidate the mechanisms underlying the reduction of A β load in APP/PS1/FTnKO mice, we studied both A β generation and clearance pathways. To assess the proteolytic processing of APP, we measured the steady-state levels of full-length APP, soluble amino-terminal fragments of APP (sAPP), and carboxyl-terminal fragments (CTF) produced by α - and β -secretase cleavages in the brain lysates of APP/PS1/FTnKO and APP/PS1 mice. Immunoblot analysis showed that neuron-specific FT deletion did not change the expression of full-length APP but significantly reduced the production of sAPP α and CTF β , with a trend reduction in sAPP β and CTF α (**Figure 7A**). Importantly, there was a trend reduction in the CTF β / α ratio and the total CTF level was significantly reduced in the brain lysates of APP/PS1/FTnKO mice compared with APP/PS1 mice (**Figure 7B**). These results indicate that neuron-specific FT deletion reduces overall APP processing in neurons; more so in the amyloidogenic processing by β -secretase, without affecting the total levels of APP, thereby leading to subsequent decreases in A β production.

Next, we assessed whether forebrain neuronal FT deletion affected A β clearance pathways. Prior studies have established that APOE and its receptor LRP1 [47] as well as A β -degrading enzymes, including insulin degrading enzyme (IDE) and neprilysin [48], play key roles in A β clearance in the brain. Thus, the steady-state levels of APOE, LRP1, IDE, and neprilysin were measured by immunoblot analysis. The results showed no significant differences in the levels of these proteins between APP/PS1/FTnKO and APP/PS1 mice

(**Figure 7, C and D**), indicating that neuronal FT deletion does not affect these A β clearance or degradation pathways.

Neuronal FT deletion counteracts aberrant mTORC1 activation and downstream lipogenesis in APP/PS1 mice

To gain more insights into the global impact of neuronal FT deletion on gene expression in the brain and the potential molecular mechanisms underlying the beneficial effects of neuronal FT suppression, we performed unbiased transcriptomic analysis on the frontal cortical samples from a cohort of APP/PS1/FTnKO, APP/PS1, and non-transgenic WT controls. There were 156 differentially expressed genes (DEGs) identified in APP/PS1/FTnKO compared with APP/PS1. Of these, 72 genes were significantly downregulated, and 84 genes were upregulated (**Figure 8A**). Functional enrichment analysis of DEGs using MSigDB (Molecular Signatures Database v5.2, <http://software.broadinstitute.org/>) Hallmark Gene set identified cholesterol homeostasis as the most significantly downregulated pathway followed by the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway (**Figure 8B** and **Figure 9B**).

Pertinently, functional enrichment analysis of 483 DEGs in APP/PS1 mice compared with non-transgenic WT controls indicated an aberrant upregulation of genes that are involved in cholesterol homeostasis and mTORC1 signaling in APP/PS1 mice (**Figure 8, C and D**). Z-score heatmap of cholesterol homeostasis and mTORC1 signaling gene clusters shows increased expression of selected genes within these two functional clusters in APP/PS1 mice compared with WT, and notably, neuronal FT deletion reduced the expression levels of many genes within these clusters to comparable levels as in WT mice (**Figure 9A**). mTORC1 is known to activate the sterol regulatory element binding proteins (SREBPs), transcription factors that regulate the expression of genes involved in lipogenesis by promoting the release of SREBPs from the SREBP cleavage-activating protein (SCAP) in the endoplasmic reticulum (ER) and translocation of SREBPs to the Golgi [49, 50]. In the Golgi, SREBPs undergo proteolytic cleavages by site-1 and site-2 proteases, liberating the soluble N-terminal mature SREBPs, which then translocate to the nucleus and bind DNA, upregulating the expression of genes for lipid/sterol synthesis. Therefore, reduced mTORC1 signaling is likely driving the downregulation of cholesterol/lipogenic genes in APP/PS1/FTnKO mice, normalizing them to the levels as in WT mice (**Figure 9, A and B**).

To examine the potential upstream regulators that drive the transcriptome changes in APP/PS1/FTnKO mice, we performed an upstream regulator analysis using Ingenuity Pathway Analysis (IPA) software. As expected, the inhibition of Raptor/mTORC1 was shown as the top key upstream regulator of observed transcriptome changes with neuronal FT deletion, followed by the inhibition of downstream SREBP2 and SCAP (**Figure 9, C and D**).

Pharmacological inhibition of Ras and Rheb farnesylation reverses aberrant activation of downstream mTORC1 signaling in APP-overexpressing SH-SY5Y cells

To corroborate the findings from transcriptomic analyses, we tested whether overexpression of APP, thereby increasing A β production, leads to overactivation of Ras and Rheb downstream signaling in neuronal cells. We compared the phosphorylation status of ERK and S6 ribosomal protein, surrogate indicators of Ras and Rheb activation, in stably

transfected APP695-overexpressing SH-SY5Y (SH-SY5Y-APP695) cells with that in mock-transfected control SH-SY5Y cells. Immunoblot analysis shows that phosphorylated ERK and S6 are significantly elevated in SH-SY5Y-APP695 cells, confirming abnormal upregulation of Ras-ERK and Rheb-mTOR-S6 pathways in neuronal cells overexpressing APP (**Figure 10, A and B**).

Next, we sought to answer whether pharmacological inhibition of FT using a specific inhibitor tipifarnib can negate the aberrant hyperactivation of Ras and Rheb-mTORC1 signaling pathways in SH-SY5Y-APP695 cells. After 48 hours of tipifarnib treatment in growth media, farnesylation status of H-Ras and Rheb as well as phosphorylation status of ERK, p70 S6 kinase (S6K), and S6 were measured using immunoblots. As expected, we observed clear mobility shift of H-Ras and Rheb bands as most of these proteins became unfarnesylated in the presence of tipifarnib (**Figure 10C**). Moreover, tipifarnib treatment also led to a significant reduction in phosphorylated S6K and S6 (**Figure 10D**), indicating that neuronal FT inhibition reverses amyloid-associated mTORC1 activation. Interestingly, tipifarnib did not affect the ERK phosphorylation even though most of H-Ras became unfarnesylated after 48 hours of treatment (**Figure 10, C and D**). This may be explained by the fact that ERK is also phosphorylated by other Ras isoforms such as N-Ras and K-Ras that can be prenylated by GGT when FT is inhibited. Taken together, these results show that inhibition of protein farnesylation reverses aberrant activation of Ras and Rheb-mTORC1 signaling associated with APP/A β overproduction.

Discussion

Findings from this study support the growing evidence that protein prenylation, particularly farnesylation, regulates the pathogenic process of AD. Previously, we have shown that systemic FT haplodeficiency rescues cognitive function as well as reducing A β load and neuroinflammation in APP/PS1 mice [27]. In the present study, we found that FT is upregulated in the brain of individuals with AD. Further, membrane-associated H-Ras, an exclusively farnesylated protein, and its downstream effector ERK activation are elevated in individuals with MCI as well as AD, suggesting upregulation of protein farnesylation and its downstream signaling pathways is an early event with primary importance in the pathogenic cascade of AD. Moreover, we show that suppressing forebrain neuronal FT alone leads to improved cognitive function and reduced neuropathology in APP/PS1 mice, revealing the specific role of neuronal FT in the pathogenesis of AD. In addition, transcriptomic analysis uncovers the global impact of neuron-specific FT deletion on cerebral gene expression and identifies the reversal of pathogenic overactivation of mTORC1 signaling network as the top contributor to the beneficial effects in APP/PS1/FTnKO mice, which is also supported by *in vitro* studies with APP-overexpressing neuronal cells.

Prior work with human brain tissue samples has shown an elevation of isoprenoid biosynthesis in AD brains compared with controls, reflected by an increase in the level of FPP and GGPP and the mRNA expression of FPPS and GGPPS [23, 24]. However, whether the protein prenylation process *per se* is affected in AD is not known. Here, studying the brain tissue samples from individuals at different stages of the disease, we found that FT is abnormally upregulated in AD, leading to subsequent elevations of protein farnesylation and overactivation of downstream signaling pathways, as evidenced by an increase in

membrane-associated H-Ras and its downstream ERK phosphorylation. Notably, the elevation of membrane-associated H-Ras and ERK phosphorylation occurs in the brain with MCI as well as AD, indicating dysregulation of protein farnesylation and downstream signaling in the early stage of AD. Consistently, other studies have shown that the level of Ras (both cytosolic and membrane/prenylated fractions) in the brain, although without the identification of specific Ras isoforms, is increased prior to both amyloid and neurofibrillary tangle pathologies [51, 52]. Increased expression of Ras and activation of downstream signaling correlate with A β levels in AD brains [19]. Importantly, here we show a particular increase in the membrane-associated H-Ras, an exclusively farnesylated protein, in both MCI and AD brains, highlighting the significance of protein farnesylation in the pathogenesis of AD.

Studies in cellular and animal models corroborate the role of protein farnesylation in multiple aspects of AD. Pharmacological treatment with farnesyltransferase inhibitors (FTI) has been shown to modulate synaptic and cognitive function as well as amyloid and tau pathologies [18-20, 53], although potential off-target effects of pharmacological agents may confound the results. Targeting FT directly by the genetic approach, we have reported that systemic FT haploinsufficiency rescues cognitive function in addition to reducing amyloid pathology in APP/PS1 mice (27). Here we show that postnatal deletion of neuron-specific FT deletion was sufficient to ameliorate memory deficit and reduce A β load in these mice. Interestingly, we also found that neuronal FT deletion significantly reduced anxiety levels in APP/PS1 mice, which was not observed in systemic FT haploinsufficient mice. This finding is similar to anxiolytic-like behavior changes reported in rats chronically treated with statins, potentially by modulating N-methyl-D-aspartate (NMDA) receptors in brain regions [54, 55]. Along with the evidence that statin treatment enhances NMDA receptor-mediated synaptic function by inhibiting FPP production and farnesylation (18, 53), these findings suggest that farnesylation-dependent mechanisms in neurons underlie the effects of statins on cognitive function and anxiety levels.

As in systemic FT haploinsufficient mice, neuron-specific FT deletion also led to reduced A β load in the brain of APP/PS1 mice, indicating the major contribution of neuronal FT-mediated lowering of A β to the attenuation of cerebral amyloid pathology. Similarly, the underlying mechanisms involved the shift of amyloidogenic to non-amyloidogenic processing of APP, although neuron-specific FT deletion resulted in a greater reduction of overall process of APP by both α - and β -secretases than systemic FT haploinsufficiency [27]. Furthermore, IDE, one of the major A β degrading enzymes, was upregulated in the brain of systemic FT haploinsufficient mice, contributing to the reduction of A β pathology [27], whereas the level of IDE was not changed in the brain of APP/PS1/FTnKO mice. This finding is consistent with the fact that IDE expression is relatively low in neurons compared with glial cells [56], thus the impact of neuronal FT deletion is not sufficient to influence the overall level of IDE in the brain. In agreement with the observation in systemic FT haploinsufficient mice, FTI treatment induces IDE secretion from microglia and increases the degradation of A β [57]. Interestingly, neuronal FT deletion, like systemic FT haploinsufficient, also led to attenuation in microglial activation in the brain, apparently due to reduced amyloid deposition. Taken together, these results demonstrate that while both APP processing and A β degradation pathways contribute to reduced cerebral A β load in systemic FT haploinsufficient mice, significant diminution of overall APP processing is the primary mechanism by which neuronal FT deletion modifies A β pathology.

Further molecular insights were provided by transcriptome analysis of frontal cortical tissue samples from different genotypes of mice. Compared with non-transgenic WT controls, the aberrant upregulation of mTORC1 signaling and cholesterol synthesis/metabolism was identified in APP/PS1 mice. Activation of mTORC1 is regulated by various growth factors and oxidative stress [58], which promotes anabolic processes including lipogenesis through SREBP activation and protein synthesis, while inhibits autophagy [59-61]. These findings are consistent with previous studies that have shown an aberrant hyperactivation of mTORC1 pathways along with the accumulation of amyloid plaques in various transgenic AD mouse models [62-64] as well as in postmortem human AD brains [65, 66]. Moreover, genetic reduction or early pharmacological suppression of mTOR has been shown to rescue cognitive deficits, reduce A β deposition and intracellular tau accumulation along with an increase of autophagy induction in AD mice [64, 67, 68]. Activation of mTORC1 also stimulates cholesterol/fatty acid synthesis through activation of SREBP1/2 [49, 50]. Our differential gene expression analysis indicates that neuronal FT deletion significantly reduces mTORC1 signaling, and the downstream SREBP1/2-mediated lipogenesis in APP/PS1 mice, restoring them to normal levels as in WT mice.

The reduction of mTORC1 signaling is most likely mediated through the reduction of farnesylated Ras and Rheb in APP/PS1/FTnKO mice, which is supported by results from *in vitro* study with APP-overexpressing neuronal cells. Farnesylation of Ras is required for its localization to the plasma membrane localization, where it interacts with membrane surface receptor tyrosine kinases (RTKs) and Ras guanine exchange factor (GEF) Sos1 [69]. Ras mediates the activation of RTKs signaling through downstream Raf-MEK-ERK and PI3K-PDK1-Akt signaling cascades, eventually leading to the inactivation of TSC1/2 complex via phosphorylation [70]. TSC1/2 is a GTPase-activating protein that hydrolyzes the active Rheb-GTP to the inactive Rheb-GDP. The inactivation of TSC1/2 through Ras-mediated RTKs signaling increases the active GTP-bound Rheb, which then directly activates mTORC1 [70, 71]. Farnesylation of Rheb is essential for the lysosomal membrane-localization of Rheb, where it encounters and activates mTORC1 [72-74]. Notably, Rheb is a major protein identified by our recent prenylomic analysis, the farnesylation of which is significantly reduced in the brain of FTnKO mice [29], as well as shown in this study by immunoblot analysis of membrane and cytosolic fractions of brain homogenates. Thus, these results support the notion that neuronal FT deletion suppresses the pathogenic mTORC1 overactivation by reducing RTKs-Ras mediated Rheb activation and Rheb-mTORC1 interaction through inhibition of farnesylation in APP/PS1 mice.

Suppression of mTORC1 signaling leads to downregulation of SREBP1/2-mediated cholesterol/lipogenic pathways, which may explain some beneficial outcomes in APP/PS1/FTnKO mice. The role of cholesterol in AD has been extensively studied. In particular, increase of cholesterol in cell membrane/lipid raft microdomains diminishes membrane fluidity, favoring amyloidogenic APP processing by β -secretase in lipid-rafts while reducing neuroprotective, non-amyloidogenic APP processing in non-lipid rafts of the plasma membrane [75-77]. Consistently, modulation of cellular cholesterol influences A β production by affecting the APP interactions with β - or γ -secretase [78-80]. In addition, overexpression of SREBP2 in APP/PS1 transgenic mice has been shown to accelerate A β accumulation and induce tau tangle formation [81]. Here we show that neuronal FT deletion corrects the heightened SREBP1/2-mediated cholesterol/lipogenic pathways in APP/PS1 mice, thus promoting non-amyloidogenic processing of APP and lowering A β production.

In summary, the present study unveils the dynamics of protein farnesylation in the pathogenic process of human AD and provides novel insights into the specific impact of neuronal FT on AD-like memory impairment and amyloid pathology in APP/PS1 mice. Our results demonstrate that abnormal upregulation of FT occurs in the early stage of human AD, and suppressing neuronal FT alone confers neuroprotective benefits against cognitive deficits and amyloid pathology through reversing pathogenic hyperactivation of mTORC1 signaling in APP/PS1 mice (**Figure 11**). In light of the recent approval of an FT inhibitor for the treatment of progeria [82], clinical trials investigating the therapeutic potential of this class of drugs for AD are warranted.

Author contributions

AJ performed experiments with postmortem human and mouse brain samples and cell cultures, analyzed the data, interpreted the results, and wrote the manuscript. SC performed mouse behavioral tests, ELISA, and immunoblot analysis of mouse brains. RZ quantified microglial activation in mouse brain sections and reviewed the manuscript. DAB provided postmortem human brain samples and data, discussion of the data, and critical review of the manuscript. MOB provided the floxed FT mice and suggestions on the manuscript. LL conceived the study, supervised the progress of all experiments, interpreted the results, and edited and finalized the manuscript. All authors reviewed the manuscript.

Acknowledgments

We thank Debra Magnuson, Karen Skish, and Gregory Klein at Rush University Alzheimer's Research Center for selecting and providing the postmortem human brain specimens, and Gunter Eckert at the University of Giessen for providing the APP695-overexpressing and control SH-SY5Y cells. We also thank Andrea Gram for breeding, maintaining and genotyping the experimental mice, Kyle LeBlanc for preparing mouse brain sections and immunostaining, and Juan E. Abrahante Lloréns at the University of Minnesota Informatics Institute for assisting with RNA-seq data analysis. AJ was partly supported by the Kwanjeong Educational Foundation Overseas Scholarship from South Korea. This work was supported in part by grants from the National Institute on Aging of the National Institutes of Health (R01AG031846, RF1AG056976, RF1AG058081, P30AG10161, and R01AG15819) and the College of Pharmacy at the University of Minnesota. ROS resources can be requested at <https://www.radc.rush.edu>.

References

1. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 261: 921-923 Doi 10.1126/science.8346443
2. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet* 41: 1088-1093
3. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet* 45: 1452-1458 Doi 10.1038/ng.2802
4. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. *Nature* 343: 425-430
5. Cole SL, Vassar R (2006) Isoprenoids and Alzheimer's disease: a complex relationship. *Neurobiol Dis* 22: 209-222
6. Hooff GP, Wood WG, Muller WE, Eckert GP (2010) Isoprenoids, small GTPases and Alzheimer's disease. *Biochim Biophys Acta* 1801: 896-905
7. Li L, Zhang W, Cheng S, Cao D, Parent M (2012) Isoprenoids and related pharmacological interventions: potential application in Alzheimer's disease. *Mol Neurobiol* 46: 64-77 Doi 10.1007/s12035-012-8253-1
8. Jeong A, Suazo KF, Wood WG, Distefano MD, Li L (2018) Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer's disease. *Critical reviews in biochemistry and molecular biology* 53: 279-310 Doi 10.1080/10409238.2018.1458070
9. McTaggart SJ (2006) Isoprenylated proteins. *Cell Mol Life Sci* 63: 255-267
10. Wang M, Casey PJ (2016) Protein prenylation: unique fats make their mark on biology. *Nat Rev Mol Cell Biol* 17: 110-122 Doi 10.1038/nrm.2015.11
11. Etienne-Manneville S, Hall A (2002) Rho GTPases in cell biology. *Nature* 420: 629-635 Doi 10.1038/nature01148
12. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D (2011) RAS oncogenes: weaving a tumorigenic web. *Nat Rev Cancer* 11: 761-774 Doi 10.1038/nrc3106
13. Langemeyer L, Frohlich F, Ungermann C (2018) Rab GTPase Function in Endosome and Lysosome Biogenesis. *Trends Cell Biol* 28: 957-970 Doi 10.1016/j.tcb.2018.06.007
14. Hottman DA, Li L (2014) Protein prenylation and synaptic plasticity: implications for Alzheimer's disease. *Mol Neurobiol* 50: 177-185 Doi 10.1007/s12035-013-8627-z
15. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K et al (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta - amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. *Proc Natl Acad Sci U S A* 98: 5856-5861.
16. Li L, Cao D, Kim H, Lester R, Fukuchi K (2006) Simvastatin enhances learning and memory independent of amyloid load in mice. *Ann Neurol* 60: 729-739
17. Boimel M, Grigoriadis N, Lourdopoulos A, Touloumi O, Rosenmann D, Abramsky O, Rosenmann H (2009) Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. *J Neuropathol Exp Neurol* 68: 314-325 Doi 10.1097/NEN.0b013e31819ac3cb
18. Mans RA, McMahon LL, Li L (2012) Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation. *Neuroscience* 202: 1-9
19. Kirouac L, Rajic AJ, Cribbs DH, Padmanabhan J (2017) Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease. *eNeuro* 4: Doi 10.1523/ENEURO.0149-

- 16.2017
20. Hernandez I, Luna G, Rauch JN, Reis SA, Giroux M, Karch CM, Boctor D, Sibih YE, Storm NJ, Diaz A et al (2019) A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy. *Science translational medicine* 11: Doi 10.1126/scitranslmed.aat3005
21. Herskowitz JH, Feng Y, Mattheyses AL, Hales CM, Higginbotham LA, Duong DM, Montine TJ, Troncoso JC, Thambisetty M, Seyfried NT et al (2013) Pharmacologic inhibition of ROCK2 suppresses amyloid-beta production in an Alzheimer's disease mouse model. *J Neurosci* 33: 19086-19098 Doi 10.1523/JNEUROSCI.2508-13.2013
22. Siano G, Caiazza MC, Olla I, Varisco M, Madaro G, Quercioli V, Calvella M, Cattaneo A, Di Primio C (2019) Identification of an ERK Inhibitor as a Therapeutic Drug Against Tau Aggregation in a New Cell-Based Assay. *Frontiers in cellular neuroscience* 13: 386 Doi 10.3389/fncel.2019.00386
23. Eckert GP, Hooff GP, Strandjord DM, Igbavboa U, Volmer DA, Muller WE, Wood WG (2009) Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients. *Neurobiol Dis* 35: 251-257
24. Pelleieux S, Picard C, Lamarre-Theroux L, Dea D, Leduc V, Tsantrizos YS, Poirier J (2018) Isoprenoids and tau pathology in sporadic Alzheimer's disease. *Neurobiol Aging* 65: 132-139 Doi 10.1016/j.neurobiolaging.2018.01.012
25. Pei JJ, Braak H, An WL, Winblad B, Cowburn RF, Iqbal K, Grundke-Iqbal I (2002) Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. *Brain Res Mol Brain Res* 109: 45-55
26. Henderson BW, Gentry EG, Rush T, Troncoso JC, Thambisetty M, Montine TJ, Herskowitz JH (2016) Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer's disease and ROCK1 depletion reduces amyloid-beta levels in brain. *J Neurochem* 138: 525-531 Doi 10.1111/jnc.13688
27. Cheng S, Cao D, Hottman DA, Yuan L, Bergo MO, Li L (2013) Farnesyltransferase haploinsufficiency reduces neuropathology and rescues cognitive function in a mouse model of Alzheimer disease. *J Biol Chem* 288: 35952-35960 Doi 10.1074/jbc.M113.503904
28. Hottman D, Cheng S, Gram A, LeBlanc K, Yuan LL, Li L (2018) Systemic or Forebrain Neuron-Specific Deficiency of Geranylgeranyltransferase-1 Impairs Synaptic Plasticity and Reduces Dendritic Spine Density. *Neuroscience* 373: 207-217 Doi 10.1016/j.neuroscience.2018.01.026
29. Qu W, Suazo KF, Liu W, Cheng S, Jeong A, Hottman D, Yuan LL, Distefano MD, Li L (2021) Neuronal Protein Farnesylation Regulates Hippocampal Synaptic Plasticity and Cognitive Function. *Mol Neurobiol* 58: 1128-1144 Doi 10.1007/s12035-020-02169-w
30. Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA (2018) Religious Orders Study and Rush Memory and Aging Project. *J Alzheimers Dis* 64: S161-S189 Doi 10.3233/JAD-179939
31. Bennett DA, Schneider JA, Aggarwal NT, Arvanitakis Z, Shah RC, Kelly JF, Fox JH, Cochran EJ, Arends D, Treinkman A et al (2006) Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. *Neuroepidemiology* 27: 169-176 Doi 10.1159/000096129
32. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, Barnes LL, Fox JH, Bach J (2002) Natural history of mild cognitive impairment in older persons. *Neurology* 59: 198-205
33. Liu M, Sjogren AK, Karlsson C, Ibrahim MX, Andersson KM, Olofsson FJ, Wahlstrom AM, Dalin M, Yu H, Chen Z et al (2010) Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer. *Proc Natl Acad Sci U S A* 107: 6471-6476

34. Tsien JZ, Chen DF, Gerber D, Tom C, Mercer EH, Anderson DJ, Mayford M, Kandel ER, Tonegawa S (1996) Subregion- and cell type-restricted gene knockout in mouse brain. *Cell* 87: 1317-1326
35. Cheng S, LeBlanc KJ, Li L (2014) Triptolide Preserves Cognitive Function and Reduces Neuropathology in a Mouse Model of Alzheimer's Disease. *PLoS One* 9: e108845 Doi 10.1371/journal.pone.0108845
36. Qu W, Li L (2020) Loss of TREM2 Confers Resilience to Synaptic and Cognitive Impairment in Aged Mice. *J Neurosci* 40: 9552-9563 Doi 10.1523/JNEUROSCI.2193-20.2020
37. Cao D, Lu H, Lewis TL, Li L (2007) Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. *J Biol Chem* 282: 36275-36282
38. Lewis TL, Cao D, Lu H, Mans RA, Su YR, Jungbauer L, Linton MF, Fazio S, LaDu MJ, Li L (2010) Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. *J Biol Chem* 285: 36958-36968
39. Hooff GP, Peters I, Wood WG, Muller WE, Eckert GP (2010) Modulation of cholesterol, farnesylpyrophosphate, and geranylgeranylpyrophosphate in neuroblastoma SH-SY5Y-APP695 cells: impact on amyloid beta-protein production. *Mol Neurobiol* 41: 341-350
40. Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome biology* 15: 550 Doi 10.1186/s13059-014-0550-8
41. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma'ayan A (2013) Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC bioinformatics* 14: 128 Doi 10.1186/1471-2105-14-128
42. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik KM, Lachmann A et al (2016) Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res* 44: W90-97 Doi 10.1093/nar/gkw377
43. Mohamed A, Saavedra L, Di Pardo A, Sipione S, Posse de Chaves E (2012) beta-amyloid inhibits protein prenylation and induces cholesterol sequestration by impairing SREBP-2 cleavage. *J Neurosci* 32: 6490-6500 Doi 10.1523/JNEUROSCI.0630-12.2012
44. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai JK (1997) K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. *J Biol Chem* 272: 14459-14464
45. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA (2003) Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. *Leukemia* 17: 1263-1293 Doi 10.1038/sj.leu.2402945
46. Berndt N, Sebt SM (2011) Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors. *Nat Protoc* 6: 1775-1791
47. Holtzman DM, Herz J, Bu G (2012) Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. *Cold Spring Harbor perspectives in medicine* 2: a006312 Doi 10.1101/cshperspect.a006312
48. Selkoe DJ (2001) Clearing the brain's amyloid cobwebs. *Neuron* 32: 177-180
49. Lewis CA, Griffiths B, Santos CR, Pende M, Schulze A (2011) Regulation of the SREBP transcription factors by mTORC1. *Biochem Soc Trans* 39: 495-499 Doi 10.1042/BST0390495
50. Eid W, Dauner K, Courtney KC, Gagnon A, Parks RJ, Sorisky A, Zha X (2017) mTORC1 activates SREBP-2 by suppressing cholesterol trafficking to lysosomes in mammalian cells. *Proc Natl Acad Sci U S A* 114: 7999-8004 Doi 10.1073/pnas.1705304114

51. Gartner U, Holzer M, Arendt T (1999) Elevated expression of p21ras is an early event in Alzheimer's disease and precedes neurofibrillary degeneration. *Neuroscience* 91: 1-5
52. Gartner U, Holzer M, Heumann R, Arendt T (1995) Induction of p21ras in Alzheimer pathology. *Neuroreport* 6: 1441-1444
53. Costa RM, Federov NB, Kogan JH, Murphy GG, Stern J, Ohno M, Kucherlapati R, Jacks T, Silva AJ (2002) Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. *Nature* 415: 526-530
54. Wang Q, Zengin A, Deng C, Li Y, Newell KA, Yang GY, Lu Y, Wilder-Smith EP, Zhao H, Huang XF (2009) High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: The association with the up-regulation of NMDA receptor binding in the rat brain. *Exp Neurol* 216: 132-138
55. Mijailovic N, Selakovic D, Joksimovic J, Mihailovic V, Katanic J, Jakovljevic V, Nikolic T, Bolevich S, Zivkovic V, Pantic Met al (2019) The anxiolytic effects of atorvastatin and simvastatin on dietary-induced increase in homocysteine levels in rats. *Mol Cell Biochem* 452: 199-217 Doi 10.1007/s11010-018-3425-6
56. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch Net al (2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *J Neurosci* 34: 11929-11947 Doi 10.1523/JNEUROSCI.1860-14.2014
57. Tamboli IY, Barth E, Christian L, Siepmann M, Kumar S, Singh S, Tolksdorf K, Heneka MT, Lutjohann D, Wunderlich Pet al (2010) Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion. *J Biol Chem* 285: 37405-37414 Doi 10.1074/jbc.M110.149468
58. Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. *Genes Dev* 18: 1926-1945 Doi 10.1101/gad.1212704
59. Wang X, Proud CG (2006) The mTOR pathway in the control of protein synthesis. *Physiology* 21: 362-369 Doi 10.1152/physiol.00024.2006
60. Kim YC, Guan KL (2015) mTOR: a pharmacologic target for autophagy regulation. *J Clin Invest* 125: 25-32 Doi 10.1172/JCI73939
61. Perluigi M, Di Domenico F, Butterfield DA (2015) mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy. *Neurobiol Dis* 84: 39-49 Doi 10.1016/j.nbd.2015.03.014
62. Zhou XW, Tanila H, Pei JJ (2008) Parallel increase in p70 kinase activation and tau phosphorylation (S262) with Abeta overproduction. *FEBS Lett* 582: 159-164 Doi 10.1016/j.febslet.2007.11.078
63. Ma T, Hoeffler CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, Tampellini D, Klann E, Blitzer RD, Gouras GK (2010) Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. *PLoS One* 5: Doi 10.1371/journal.pone.0012845
64. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. *J Biol Chem* 285: 13107-13120 Doi 10.1074/jbc.M110.100420
65. An WL, Cowburn RF, Li L, Braak H, Alafuzoff I, Iqbal K, Iqbal IG, Winblad B, Pei JJ (2003) Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. *Am J Pathol* 163: 591-607 Doi 10.1016/S0002-9440(10)63687-5
66. Tramutola A, Triplett JC, Di Domenico F, Niedowicz DM, Murphy MP, Coccia R, Perluigi M, Butterfield DA (2015) Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnesic mild cognitive impairment and late-stage AD. *J Neurochem* 133: 739-749 Doi 10.1111/jnc.13037
67. Spilman P, Podlutska N, Hart MJ, Debnath J, Gorostiza O, Bredesen D,

- Richardson A, Strong R, Galvan V (2010) Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. *PLoS One* 5: e9979 Doi 10.1371/journal.pone.0009979
68. Caccamo A, De Pinto V, Messina A, Branca C, Oddo S (2014) Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. *J Neurosci* 34: 7988-7998 Doi 10.1523/JNEUROSCI.0777-14.2014
69. Degirmenci U, Wang M, Hu J (2020) Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. *Cells* 9: Doi 10.3390/cells9010198
70. Bockaert J, Marin P (2015) mTOR in Brain Physiology and Pathologies. *Physiol Rev* 95: 1157-1187 Doi 10.1152/physrev.00038.2014
71. Parmar N, Tamanoi F (2010) Rheb G-Proteins and the Activation of mTORC1. *The Enzymes* 27: 39-56 Doi 10.1016/S1874-6047(10)27003-8
72. Castro AF, Rebhun JF, Clark GJ, Quilliam LA (2003) Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. *J Biol Chem* 278: 32493-32496 Doi 10.1074/jbc.C300226200
73. Basso AD, Mirza A, Liu G, Long BJ, Bishop WR, Kirschmeier P (2005) The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. *J Biol Chem* 280: 31101-31108 Doi 10.1074/jbc.M503763200
74. Hanker AB, Mitin N, Wilder RS, Henske EP, Tamanoi F, Cox AD, Der CJ (2010) Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling. *Oncogene* 29: 380-391 Doi 10.1038/onc.2009.336
75. Barrett PJ, Song Y, Van Horn WD, Hustedt EJ, Schafer JM, Hadziselimovic A, Beel AJ, Sanders CR (2012) The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. *Science* 336: 1168-1171 Doi 10.1126/science.1219988
76. Yang X, Sun GY, Eckert GP, Lee JC (2014) Cellular membrane fluidity in amyloid precursor protein processing. *Mol Neurobiol* 50: 119-129 Doi 10.1007/s12035-014-8652-6
77. Arbor SC, LaFontaine M, Cumbay M (2016) Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores. *The Yale journal of biology and medicine* 89: 5-21
78. Urano Y, Hayashi I, Isoo N, Reid PC, Shibasaki Y, Noguchi N, Tomita T, Iwatsubo T, Hamakubo T, Kodama T (2005) Association of active gamma-secretase complex with lipid rafts. *J Lipid Res* 46: 904-912 Doi 10.1194/jlr.M400333-JLR200
79. Marquer C, Devaues V, Cossec JC, Liot G, Lecart S, Saudou F, Duyckaerts C, Leveque-Fort S, Potier MC (2011) Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. *Faseb J* 25: 1295-1305 Doi 10.1096/fj.10-168633
80. Langness VF, van der Kant R, Das U, Wang L, Chaves RDS, Goldstein LSB (2021) Cholesterol-lowering drugs reduce APP processing to Abeta by inducing APP dimerization. *Mol Biol Cell* 32: 247-259 Doi 10.1091/mbc.E20-05-0345
81. Barbero-Camps E, Fernandez A, Martinez L, Fernandez-Checa JC, Colell A (2013) APP/PS1 mice overexpressing SREBP-2 exhibit combined Abeta accumulation and tau pathology underlying Alzheimer's disease. *Hum Mol Genet* 22: 3460-3476 Doi 10.1093/hmg/ddt201
82. Mullard A (2021) The FDA approves a first farnesyltransferase inhibitor. *Nat Rev Drug Discov* 20: 8 Doi 10.1038/d41573-020-00213-x

Figure Legends

Figure 1. The mevalonate/isoprenoid and protein prenylation pathways. Farnesyl pyrophosphate (FPP) is derived from mevalonate, serving as the branching point for the non-steroid isoprenoid pathway and the sterol synthesis pathway. FPP and geranylgeranyl pyrophosphate (GGPP) are used for protein farnesylation and geranylgeranylation (collectively called protein prenylation) by the catalytic actions of farnesyltransferase (FT) and geranylgeranyl transferases (GGTs), respectively. HMG-CoA: 3-Hydroxy-3-methylglutaryl-CoA, HMGCR: Hydroxymethylglutaryl-CoA reductase, GPPS: Geranyl pyrophosphate synthase, FPPS: Farnesyl pyrophosphate synthase, GGPPS: Geranylgeranyl pyrophosphate synthase, FT: Farnesyltransferase, GGT: Geranylgeranyltransferase-1/2.

Figure 2. Elevation of FT in AD brains accompanied by an increase in H-Ras farnesylation and ERK activation in brains with MCI as well as AD. (A) Immunoblot analysis of FT- β subunit and GGT-1 β subunit in the prefrontal cortical tissue lysates from individuals with no cognitive impairment (NCI), mild cognitive impairment (MCI), or Alzheimer's disease (AD). (B, C) Densitometry analysis of FT- β and GGT-1 β immunoblots normalized by tubulin with the levels in the NCI group set as 100%. (D, E) Immunoblot analysis of total H-Ras and densitometric analysis of H-Ras normalized by β -actin. (F, G) Immunoblot analysis of H-Ras in the membrane (M) and cytosolic (C) fractions. Immunoblot analysis of ER membrane-associated calnexin and cytosolic GAPDH confirms the separation of membrane-associated and cytosolic proteins. Ratios of membrane-associated (farnesylated) H-Ras to cytosolic (unfarnesylated) H-Ras were compared relative to the NCI group. (H, I) Immunoblot analysis of phospho-ERK (P-ERK) and total ERK in the brain tissue lysates. Ratios of P-ERK (activated) to total ERK were compared relative to the NCI group. (J, K) Positive correlations of membrane (farnesylated) H-Ras with FT and P-ERK levels by Pearson correlation analysis. $n=20$ per group; (B, C and E) Kruskal-Wallis, 2-tailed with post-hoc Dunn's multiple comparison test; (G and I) Wilcoxon signed rank-order test, 2-tailed; * $p < 0.05$; *** $p < 0.005$; **** $p < 0.0001$.

Figure 3. Generation of forebrain neuron-specific FT knockout mice. (A) Schematic representation of the 3-step breeding strategy to generate APP/PS1 mice harboring homozygous FT knockout in forebrain neurons (APP/PS1/FTnKO) and littermate controls. (B) Representative immunoblot images of FT- β and HDJ-2, a well-known farnesylated protein that is widely used as a marker for farnesylation, in cortical, hippocampal, cerebellar tissue homogenates of WT and FTnKO mice at 3 and 6 months of age. Unfarnesylated HDJ-2 band is detected in the forebrain region (cortex and hippocampus), but not in the cerebellum, of FTnKO mice at 3 months, and the level is elevated at 6 months, confirming both brain region- and age-dependent deletion of FT. (C) Immunoblot analysis of representative small GTPases in membrane (M) and cytosolic (C) fractions of cortical tissue lysates of FTnKO mice compared with WT controls ($n=3$ /genotype). Membrane-associated FT substrates, farnesylated H-Ras and Rheb, are reduced significantly or trending reduction in FTnKO compared with WT controls, whereas membrane levels of GGT substrate RhoA are not affected, confirming the specificity of FT deletion. Wilcoxon signed rank-order test, 2-tailed; * $p < 0.05$.

Figure 4. Improvement of spatial learning and memory in neuronal FT knockout

APP/PS1 mice. (A) Schematic representation of the Morris water maze testing paradigm. **(B)** Escape latencies during the acquisition phase of the test. Repeated measures two-way ANOVA with post-hoc Sidak's multiple comparisons shows a significant interaction between genotype and day during the test ($F(4, 90) = 3.188$, $p = 0.0169$), indicating a steeper/faster learning curve in APP/PS1/FTnKO mice; * $p < 0.05$. **(C)** Percentage of time spent in the target quadrant in the probe trial. Time spent in the target quadrant due to chance (25%) is marked with a dashed line. $n=11-13$ mice/genotype at 9 months; unpaired Student's t-test, 1-tailed; * $p < 0.05$.

Figure 5. Reduced A β accumulation in APP/PS1/FTnKO mice. A β was serially extracted from the cortex and hippocampus using carbonate and guanidine buffers. A β 40 and A β 42 levels in each fraction were measured by ELISA. **(A)** Carbonate- and **(B)** guanidine-soluble A β 40 and A β 42 in the cortex of APP/PS1 and APP/PS1FTnKO mice. **(C)** Carbonate- and **(D)** guanidine-soluble A β 40 and A β 42 in the hippocampus of APP/PS1 and APP/PS1FTnKO mice. $n=8$ mice/genotype; unpaired Student's t-test, 2-tailed; # $p = 0.07$; * $p < 0.05$; ** $p < 0.01$.

Figure 6. Reduced A β deposition in APP/PS1/FTnKO mice. **(A)** Representative brain sections from APP/PS1 and APP/PS1/FTnKO mice immunostained with anti-A β antibody (6E10). Scale bar, 500 μ m. **(B, C)** Cortex and Hippocampal A β loads determined by immunohistochemical and morphometric analyses with the A β -positive area in the APP/PS1 control group set as 100%. **(D, E)** Quantification of small (<20 μ m), medium (20-50 μ m), and large (>50 μ m) amyloid plaques in the cortex and hippocampus. **(F)** Representative brain sections from APP/PS1 and APP/PS1/FTnKO mice immunostained for activated microglia using anti-IBA1 antibody. Scale bar, 500 μ m. **(G, H)** Microglial activation in the cortex and hippocampus determined by morphometric analyses with the IBA1-positive area in the APP/PS1 control group set as 100%. $n=8$ mice/genotype; Student's t-test, 2-tailed; * $p < 0.05$; *** $p < 0.001$.

Figure 7. Reduced APP proteolytic processing in APP/PS1/FTnKO mice. (A, B) Immunoblots and densitometric analysis of full-length APP (FL-APP), and APP cleavage products, carboxyl-terminal fragments (CTF α and CTF β), and amino-terminal fragment of APP (sAPP α and sAPP β). Protein levels were normalized by the amount of tubulin with the levels in the APP/PS1 control group set as 100%. **(C, D)** Immunoblots and densitometric analysis of proteins involved in A β clearance pathways including APOE, LRP1, IDE, and neprilysin. Protein levels were normalized by the amount of tubulin or GAPDH, and the levels in the control group set as 100%. $n=8$ /genotype; Student's t-test, 2-tailed; # $p = 0.08$; * $p < 0.05$; ** $p < 0.01$.

Figure 8. Transcriptomic analysis of frontal cortex from APP/PS1/FTnKO, APP/PS1, and WT mice. **(A)** Volcano plot for cortical transcriptome analysis of APP/PS1/FTnKO versus APP/PS1 mice at 9-10 months ($n=6$ /genotype). Red and blue points represent upregulated and downregulated genes below the significance threshold ($FDR < 0.05$), respectively. **(B)** Top enriched pathways categorized by mSigDB Hallmark gene set database in differentially downregulated genes in APP/PS1/FTnKO mice compared with APP/PS1 controls. **(C)** Volcano plot for cortical transcriptome of WT ($n=5$) versus APP/PS1 mice ($n=6$) at 9-10 months. **(D)** Top enriched mSigDB Hallmark pathways of significantly upregulated genes ($FDR < 0.05$) in the cortex of APP/PS1 mice compared with WT controls.

Figure 9. Normalization of mTORC1 and SREBP-mediated lipogenesis pathways in the cortex of APP/PS1/FTnKO mice. (A) Heatmap of RNA expression z-scores computed for selected genes in the cholesterol homeostasis and mTORC1 signaling pathways across the three genotypes. The color gradient of the bars on the right reflect the log₂(fold change) of the genes, and the genes that are significantly downregulated or upregulated (FDR < 0.05) are indicated by an asterisk (*). (B) Table of top downregulated mSigDB Hallmark pathways and the corresponding differentially expressed genes (DEGs) in APP/PS1/FTnKO mice compared with APP/PS1 mice. (C) Table of key transcriptional regulators identified through upstream regulator analysis using Ingenuity Pathway Analysis (IPA) software. Based on the log₂(fold change) of downstream target genes, the activity of the upstream regulator is predicted using activation z-score. (D) Network of Raptor, a regulatory associated protein of mTOR, and its targeted genes. Edges (lines between nodes) represent direct (solid lines) and indirect (dashed lines) interactions as supported by information in the Ingenuity knowledge base.

Figure 10. Pharmacological inhibition of FT reverses the hyperactivation of Ras-Rheb-mTORC1 signaling in SH-SY5Y-APP695 cells. (A) Immunoblot analysis of FL-APP and downstream targets of Ras-Rheb-mTORC1 signaling, including ERK and ribosomal protein S6, in the lysates of SH-SY5Y-APP695 mock-transfected control cells. (B) Densitometric analysis of immunoblots normalized by the amount of GAPDH or total proteins for phosphorylated proteins (P-ERK, P-Akt, P-S6) with the levels in the control group set as 100%. n=6 replicates from 2 independent experiments. (C) Immunoblot analysis of farnesylation status of H-Ras and Rheb, and (D) phosphorylation status of downstream targets of Ras and Rheb in the lysates of SH-SY5Y-APP695 WT cells after treated with vehicle (DMSO) or 1 μM tipifarnib for 48 hours. (E) Densitometric analysis of immunoblots of P-ERK, P-S6K, and P-S6 normalized by the amount of total ERK, S6K, and S6 with the levels in the control group set as 100%. n=6 replicates from 2 independent experiments. Student's t-test, 2-tailed; * $p < 0.05$; *** $p < 0.001$; **** $p < 0.0001$.

Figure 11. Schematic illustration of FT upregulation pathways leading to AD and reversal by FT deletion or inhibition. Aberrant upregulation of FT/protein farnesylation increases the membrane association of farnesylated proteins, including Ras and Rheb, and their interactions with downstream effectors, leading to hyperactivation of mTORC1 signaling and AD. Deletion or inhibition of FT results in the reduced membrane association of Ras and Rheb and reverses the pathogenic activation of the signaling pathway.

Table 1. Human participant demographics

	NCI (No cognitive impairment)	MCI (Mild cognitive impairment)	AD (Alzheimer's dementia)
# Samples	20	20	20
Age at Death (yr)	87.16 ± 3.39	87.42 ± 3.32	87.38 ± 3.58
Male/Female	4/16	4/16	4/16
Education (yr)	17.60 ± 1.39	17.60 ± 1.39	17.70 ± 1.49
Post-mortem Interval (hr)	6.21 ± 3.96	9.31 ± 3.96	6.97 ± 3.96
Total amyloid- β (% area)	4.27 ± 3.76	1.90 ± 1.80	3.92 ± 3.27
Tau tangle density	3.88 ± 0.55	3.61 ± 0.98	10.47 ± 10.74

Table 2. Exploratory activities and anxiety levels of APPPS1 and APP/PS1/FTnKO mice

	APPPS1 (n=13)	APP/PS1/FTnKO (n=11)
Motor activity (open field)		
Path length (m)		
Day 1	20.37 ± 4.65	13.48 ± 4.59
Day 2	14.36 ± 3.88	8.95 ± 2.82
Day 3	11.92 ± 3.78	5.94 ± 1.74
Percentage of time in the central zone (%)		
Day 1	1.72 ± 0.78	1.23 ± 0.74
Day 2	0.29 ± 0.14	0.05 ± 0.05
Day 3	0.28 ± 0.14	0.02 ± 0.02
Anxiety (elevated plus-maze)		
Entries to open arms		
Day 1	7.53 ± 1.58	6.45 ± 1.38
Day 2	2.54 ± 0.55	7.09 ± 2.01
Percentage of time in open arms		
Day 1	16.18 ± 3.85	37.12 ± 10.51
Day 2	6.28 ± 1.93	24.08 ± 8.63*

* $p < 0.05$, repeated measures two-way ANOVA with post-hoc Sidak's multiple comparisons.

Table 3. Antibodies used in this study

Primary antibodies					
Target	Vendor	Catalog#	Source/Isotype	M.W.	Application
β-actin (C4)	Millipore	MAB1501	Mouse/IgG _{1k}	43 kD	WB
Pan-Akt (40D4)	Cell Signaling	2920	Mouse/IgG ₁	60 kD	WB
Phospho-Akt (Ser473) (D9E)	Cell Signaling	4060	Rabbit/IgG	60 kD	WB
Beta-Amyloid (CT695)	Invitrogen	51-2700	Rabbit/IgG	10-12, 110 kD	WB
Beta-Amyloid ₁₋₁₆ (6E10)	BioLegend	SIG-39320	Mouse/IgG _{1k}	4-16, 100 kD	IHC
Soluble APP-alpha (2B3)	Clonotech	11088	Mouse/IgG _{2b}	100 kD	WB
Soluble APP-beta-swe (6A1)	Clonotech	10321	Mouse/IgG ₃	100 kD	WB
ApoE (3B3C32)	BioLegend	674802	Rat/IgG _{2ak}	34 kD	WB
Calnexin (H-70)	Santa Cruz	Sc-11397	Rabbit/IgG	90 kD	WB
Phospho-ERK1/2 (Thr202/Tyr204)	Cell Signaling	9101	Rabbit/IgG	42, 44 kD	WB
ERK1/2	Cell Signaling	9102	Rabbit/IgG	42, 44 kD	WB
Farnesyl transferase β subunit (X28)	Santa Cruz	sc-137	Rabbit/IgG	48 kD	WB
GAPDH (V-18), HRP-conjugated	Santa Cruz	Sc-20357 HRP	Goat/IgG	36 kD	WB
GAPDH (6C5)	Invitrogen	AM4300	Mouse/IgG ₁	36 kD	WB
Geranylgeranyl transferase β subunit (H-3)	Santa Cruz	Sc-376655	Mouse/ IgG _{1k}	42 kD	WB
H-Ras (C20)	Santa Cruz	sc-520	Rabbit/IgG	21 kD	WB
H-Ras	ProteinTech	18295-1-AP	Rabbit/IgG	21 kD	WB
HDJ2 (KA2A5.6)	Invitrogen	MA5-12748	Mouse/IgG1	40 kD	WB
IBA1	Wako	019-19741	Rabbit/IgG	16 kD	IHC
IDE	Sigma-aldrich	AB9210	Rabbit/IgG	110 kD	WB
LRP1 (6F8)	Sigma-aldrich	MABN1796	Mouse/ IgG _{1k}	85 kD	WB
Neprilysin (F-4)	Santa Cruz	Sc-46656	Mouse/ IgG _{1k}	100 kD	WB
Rab7 (117)	Sigma-aldrich	R8779	Mouse/IgG _{2b}	24 kD	WB
Rheb (B-12)	Santa Cruz	Sc-271509	Mouse/IgG _{2bk}	21 kD	WB
RhoA (26C4)	Santa Cruz	sc-418	Mouse/IgG _{1k}	24 kD	WB
p-S6 ribosomal protein	Cell Signaling	2215	Rabbit/IgG	32 kD	WB

(Ser240/244)					
S6 ribosomal protein (5G10)	Cell Signaling	2217	Rabbit/IgG	32 kD	WB
Phospho-p70 S6 Kinase (Thr389)(108D2)	Cell Signaling	9234	Rabbit/IgG	70, 85 kD	WB
p70 S6 Kinase (49D7)	Cell Signaling	2708	Rabbit/IgG	70, 85 kD	WB
α -tubulin (B-5-1-2)	Sigma-aldrich	T5168	Mouse/IgG ₁	50 kD	WB
Secondary antibodies/binding proteins					
Target	Vendor	Catalog #	Source/Isotype	Application	
anti-rabbit IgG, HRP-conjugated	Santa Cruz	Sc-2357	Mouse/IgG	WB	
anti-mouse IgG, HRP-conjugated	Santa Cruz	Sc-2307	Donkey/IgG	WB	
mouse IgG _k light chain binding protein, HRP-conjugated	Santa Cruz	sc-56102	N/A	WB	
anti-rabbit IgG, HRP-conjugated	Santa Cruz	Sc-2305	Donkey/IgG	WB

Figure 6. Reduced Aβ deposition in APP/PS1/FTnKO mice. (A) Representative brain sections from APP/PS1 and APP/PS1/FTnKO mice immunostained with anti-Aβ antibody (6E10). Scale bar, 500 μm. (B, C) Cortex and Hippocampal Aβ loads determined by immunohistochemical and morphometric analyses with the Aβ-positive area in the APP/PS1 control group set as 100%. (D, E) Quantification of small (<20 μm), medium (20-50 μm), and large (>50 μm) amyloid plaques in the cortex and hippocampus. (F) Representative brain sections from APP/PS1 and APP/PS1/FTnKO mice immunostained for activated microglia using anti-IBA1 antibody. Scale bar, 500 μm. (G, H) Microglial activation in the cortex and hippocampus determined by morphometric analyses with the IBA1-positive area in the APP/PS1 control group set as 100%. n=8 mice/genotype; Student's t-test, 2-tailed; * $p < 0.05$; *** $p < 0.001$.